| Autor: |
Cankar Dal H; From the Department of Intensive Care Unit, Ankara City Hospital, Ankara, Turkey., Eren N, Kazanci D, Yekeler E, Türkkan S, Turan S |
| Jazyk: |
angličtina |
| Zdroj: |
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation [Exp Clin Transplant] 2022 Aug; Vol. 20 (8), pp. 786-788. Date of Electronic Publication: 2021 Sep 20. |
| DOI: |
10.6002/ect.2021.0223 |
| Abstrakt: |
In the COVID-19 pandemic presently affecting the whole world, solid-organ transplant recipients under immunosuppressive therapy are at higher risk than the general population. COVID-19 infection primarily affects the lungs, and so the risk is further increased in lung transplant recipients. The course of COVID-19 in lung transplant recipients is unclear. Here, we present the intensive care follow-up and treatment process of a bilateral lung transplant recipient who developed acute respiratory failure due to COVID-19, for whom the final outcome was favorable. Antiviral treatment was initiated for the 53-year-old male patient with COVID-19 pneumonia, and in the following hyperinflammatory phase, high-dose pulse steroid therapy was administered. The patient was followed up with high- flow nasal oxygen, and then he was supported by intermittent noninvasive mechanical ventilation as hypoxia became more severe. With these noninvasive ventilation strategies and good intensive care procedures, the patient was successfully discharged. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
